日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

一项针对活化磷脂酰肌醇3-激酶δ (PI3Kδ) 综合征 (APDS) 的 leniolisib 随机、安慰剂对照 III 期试验：青少年和成人亚组分析

期刊:Clinical Immunology
影响因子:3.8
doi:10.1016/j.clim.2024.110400
Rao, V Koneti; Šedivá, Anna; Dalm, Virgil A S H; Plebani, Alessandro; Schuetz, Catharina; Shcherbina, Anna; Trizzino, Antonino; Zharankova, Yulia; Orpia, Alanvin; Kulm, Elaine; Webster, Sharon; Körholz, Julia; Lougaris, Vassilios; Rodina, Yulia; Conlon, Niall; Coulter, Tanya; Bradt, Jason; Relan, Anurag; Uzel, Gulbu
信号转导
发表日期：2025
文献求助 收藏

Interim analysis: Open-label extension study of leniolisib for patients with APDS

中期分析：leniolisib治疗APDS患者的开放标签扩展研究

期刊:Journal of Allergy and Clinical Immunology
影响因子:11.2
doi:10.1016/j.jaci.2023.09.032
Rao, V Koneti; Kulm, Elaine; Šedivá, Anna; Plebani, Alessandro; Schuetz, Catharina; Shcherbina, Anna; Dalm, Virgil A; Trizzino, Antonino; Zharankova, Yulia; Webster, Sharon; Orpia, Alanvin; Körholz, Julia; Lougaris, Vassilios; Rodina, Yulia; Radford, Kath; Bradt, Jason; Relan, Anurag; Holland, Steven M; Lenardo, Michael J; Uzel, Gulbu
发表日期：2024
文献求助 收藏

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

一项针对晚期癌症患者的I期临床试验，采用基于多靶点重组腺病毒5（CEA/MUC1/Brachyury）的免疫疗法疫苗方案

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2019-0608
Gatti-Mays, Margaret E; Redman, Jason M; Donahue, Renee N; Palena, Claudia; Madan, Ravi A; Karzai, Fatima; Bilusic, Marijo; Sater, Houssein Abdul; Marté, Jennifer L; Cordes, Lisa M; McMahon, Sheri; Steinberg, Seth M; Orpia, Alanvin; Burmeister, Andrea; Schlom, Jeffrey; Gulley, James L; Strauss, Julius
肿瘤
MUC1
肿瘤免疫
微生物学
免疫/内分泌
发表日期：2020
文献求助 收藏

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

BN-CV301（一种靶向MUC1和CEA并含有共刺激分子的重组痘病毒疫苗）的I期剂量递增试验

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-19-0183
Gatti-Mays, Margaret E; Strauss, Julius; Donahue, Renee N; Palena, Claudia; Del Rivero, Jaydira; Redman, Jason M; Madan, Ravi A; Marté, Jennifer L; Cordes, Lisa M; Lamping, Elizabeth; Orpia, Alanvin; Burmeister, Andrea; Wagner, Eva; Pico Navarro, Cesar; Heery, Christopher R; Schlom, Jeffrey; Gulley, James L
微生物学
MUC1
发表日期：2019
文献求助 收藏